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1 | INTRODUCTION  
 
Hypertension or high blood pressure (BP) is a key modifiable risk fac- 
tor for cardiovascular diseases (CVD), hence being the main cause of 
global morbidity and mortality (Bochud, Marques-Vidal, Burnier, & 
Paccaud, 2011; Forouzanfar et al., 2016; Lawes, Vander Hoorn, & 
Rodgers, 2008). Around 40% of the global population has raised BP 
and the global burden of hypertension is estimated to exceed 1.6 bil- 
lion by 2025 (Egan, Kjeldsen, Grassi, Esler, & Mancia, 2019), leading to 
a subsequent increase in disability-adjusted life years and deaths 
related to hypertension (Forouzanfar et al., 2017). Furthermore, the 
economic burden of hypertension is another challenge, with estimated 
medical cost attributed to high BP of approximately $51.2 billion a 
year in the United States (Benjamin et al., 2017). 
Among the adult population, an optimal BP level is defined as less 
than 120/80 mmHg, forecasting a lower risk of adverse cardiovascular 
events (Whelton, Carey, & Aronow, 2018). Lifestyle modification 
along with healthy dietary interventions, such as engagement in physi- 
cal and/or exercise activity, body weight control, reduced alcohol, and 
salt intake, diets rich in fruits and vegetables, and low-fat dairy prod- 
ucts are well-known nonpharmacological approaches for improving 
BP control (Appel et al., 2006; Whelton et al., 2002). Over the years, a 
particular interest has grown in the role of nutrition and its impact on 
BP (Appel et al., 1997; Appel et al., 2005). Accordingly, Dietary 
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The impact of walnuts on blood pressure (BP) is not a well-established fact. Although sev- 
eral studies have assessed the effects of walnut consumption on BP, results are con- 
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help control elevated BP without medications (NIH, 2018). Along with 
fruits, vegetables and other prescribed healthiest foodstuffs, the 
DASH includes 1 serving per day of nuts (Challa, Tadi, & Uppaluri, 2020), 
which are dietary components associated with improvement in cardiovas- 
cular healthy, as evidenced in meta-analyses (Del Gobbo, Falk, Feldman, 
Lewis, & Mozaffarian, 2015; Mejia et al., 2014). 
Walnut, a nut from any tree of genus Juglans, is a rich source of 
antioxidants, phytosterols, dietary fibers, protein, and fat, especially 
polyunsaturated fatty acids (PUFA), such as the α-linolenic acid (ALA)/ 
omega-3 (n-3) (Kris-Etherton, Hu, Ros, & Sabaté, 2008; Orsavova, 
Misurcova, Ambrozova, Vicha, & Mlcek, 2015; Souza, Gomes, Naves, & 
Mota, 2015). Compared to other nuts and vegetable oils, mainly those 
with a high monounsaturated fatty acids (MUFA) content, walnut con- 
tains a greater amount and types of polyphenolic compounds (Li, Tsao, 
Yang, Kramer, & Hernandez, 2007). 
Many studies have evaluated the effects of walnut-enriched diet on 
different metabolic parameters, such  as  total  cholesterol  (Morgan 
et   al.,   2002),   low-density   lipoprotein    cholesterol    (LDL-C)  
(Wu et al., 2014), BP (Del Gobbo et al., 2015), and vascular function (Del 
Gobbo et al., 2015). Despite a considerable body of evidence on the 
effect of walnut intake on cardiovascular health (Banel & Hu, 2009; Din 
et al., 2011; Ma et al., 2010; Ros et al., 2004), it is unclear whether wal- 
nut consumption, per se, is a useful tool for controlling or lowering 
BP. We therefore performed a meta-analysis of randomized clinical trials 
(RCTs) to examine the overall impact of walnut consumption on both 
diastolic and systolic BP values, working on doses and length of interven- 
tion in order to translate the findings into a clinical conclusion. 
 
 
2 | METHODS 
 
2.1 | Design 
 
A systematic review and meta-analysis was performed in accordance 
with the Preferred Reporting Items for Systematic Reviews and Meta- 




2.2 | Search strategy 
 
We searched four databases including PubMed/Medline, Scopus, Web 
of sciences, and Google Scholar to identify articles that examined the 
effects of walnut intake on SBP and DBP, whose search strategy was 
conducted from inception up to April, 2020. The search process was 
performed using a combination of following keywords and medical sub- 
ject headings (MeSH) terms: (“walnut” OR “walnuts” OR “juglans”) AND 
(“blood pressure” OR “systolic blood pressure” OR “diastolic blood pres- 
sure” OR “SBP” OR “DBP” OR “hypertension”) AND (“clinical trials” OR 
“clinical trial” OR “cross-over studies” OR “double-blind method” OR 
“single-blind method” OR “random allocation” OR “RCT” OR “random” 
OR “randomly” OR “placebo” OR “assignment” OR “intervention stud- 
ies” OR “intervention” OR “controlled trial” OR “randomized” OR “Trial” 
OR “randomised”). Moreover, we undertook an explicit hand-searching 
for all reference lists to find additional relevant articles that may have 
been dropped from initial search. 
 
 
2.3 | Selection criteria 
 
We considered studies that: (a) were employed in a randomized con- 
trolled design; (b) reported BP measurements at the baseline and at 
the end of the study for both walnut and control groups; (c) were con- 
ducted on adults. We excluded articles if: (a) the study was conducted 
on children, pregnant women or animals; (b) without a control group; 
(c) BP data have not been reported; (d) reported duplicate data (i.e., BP 
values reported from the same study in two or more publications); 
(e) walnut intake combined with some medications, supplements and 
other nuts; (f) the study was not published in a peer-reviewed journal 
(conference papers, dissertations, and protocols). 
 
 
2.4 | Data extraction 
 
The required data from each of the selected studies were extracted 
independently by two investigators. A third, senior meta-researcher, 
was involved to discuss and resolve any disagreements. Following 
data were extracted from each of the studies: study design, the first 
author's surname, publication year, country, sample size, gender, par- 
ticipants' mean age, treatment duration, type of intervention, dose of 
walnut (g/day), health status, type of control, and results of BP. In 
addition, we contacted the corresponding authors in case of missing 
data or need for additional information for a specific study. 
 
 
2.5 | Quality assessment 
 
Cochrane scoring system was used to assess the methodological qual- 
ity and risk of bias in the included studies (Moher et al., 2009). This 
tool includes domains working on: possible sources of bias in RCTs, 
including the random sequence generation; allocation concealment 
conditions; awareness of the allocated intervention; blinding of out- 
come assessment; incomplete outcome data; selective reporting; and 
other biases. Domains were classified as “high risk,” “low risk,” or 
“unclear.” We categorized each publication as having poor, fair, or 
good quality, according to the Agency for Healthcare Research and 
Quality (AHRQ) standards. Publications were judged to be of poor 
quality if the allocation concealment conditions, random sequence 
generation, and blinding status reveal unclear or at high risk of bias. 
 
 
2.6 | Data synthesis and statistical analysis 
 
We used the STATA software (version 14) to perform the meta-analy- 
sis. The investigators extracted the mean and SD of SBP/DBP at the 
baseline and at end of the studies in both intervention and control 
 
 
groups. Upon data not obtained, the mean difference was derived by 
standard calculations. If mean (±SD) of SBP/DBP was not directly 
presented and a standard error of the mean (SEM) was accessible 
instead of SD, we used the conversion to SD through this formula: 
SD1/4SEM_ _n, being “n” the number of participants in each group. 
When no SDs were described for net alteration in BP, the following 
formula was  applied:  SDalteration  =  square  root  [(SDpre-intervention)2  þ 
(SDpost-intervention)2_(2_R_SDpre-intervention_SDpost-intervention)] 
(Higgins, 2011; Hozo, Djulbegovic, & Hozo, 2005). 
Random-effects model developed by Der Simonian was used in 
order to estimate effect sizes, with values represented by weighted 
mean difference (WMD) and 95% confidence interval (CI). Employing 
in I2 statistic, we quantified heterogeneity in the meta-analyses, with 
values greater than 50% revealing high level. A priori subgroup analy- 
sis of doses, duration of intervention, and healthy status was executed 
to identify potential sources of heterogeneity. 
Nonlinear potential effects of walnut doses (g/day) and duration 
(weeks) of intervention were assessed by fractional polynomial modeling 
(Fan, 2018). Sensitivity analysis was also accomplished to investigate the 
extent of individual study interference using the leave-one-out method. 
Publication bias was evaluated by means of visual calculation of funnel 
plots and Egger's tests (Egger, Smith, Schneider, & Minder, 1997). 
 
 
3 | RESULTS 
 
3.1 | Study selection 
 
Initial database search returned 156 articles and, after removing dupli- 
cates, 97 articles remained. After screening titles and abstracts, 72 articles 
were removed and 25 were yielded for full-text review. Finally, 17 arti- 
cles with 18 comparisons were included in this meta-analysis (Figure 1). 
 
 
3.2 | Characteristics of the included studies 
 
Although we firstly worked on a comprehensive search from inception 



































FIG U R E 1 Flow chart for study examined 
and included into the meta-analysis 
159 articles identified through 
PubMed, Scopus, Web of sciences 
and Google scholar databases 
searching 
59 duplicates articles were 
removed 
97 articles screened 
72 articles excluded based on 
title and abstract 
25 full-text articles 
examined for eligibility 
8 full-text articles excluded 
• no control group 
• short duration 
• studies included no data of interest 









between 2004 and 2020. In general, studies before 2004 did not pro- 
vide adequate data for our analyses. Studies were conducted in the 
United States (Al Abdrabalnabi et al., 2020; Katz et al., 2012; Ma 
et al., 2010; Njike, Ayettey, Petraro, Treu, & Katz, 2015; Rock, Flatt, 
Barkai, Pakiz, & Heath, 2017; Spaccarotella et al., 2008; Tindall   
et al., 2019), Republic of Korea (Hwang et al., 2019), Australia 
(Ndanuko, Tapsell, Charlton, Neale, & Batterham, 2018), Iran (Fatahi, 
Haghighatdoost,  Larijani,  &  Azadbakht,  2019;  Nezhad,  Aghasadeghi, 
Hakimi,  Yarmohammadi,  &  Nikaein,  2016),  United  Kingdom  (Din 
et al., 2011), Spain (Olmedilla-Alonso et al., 2008; Ros et al., 2004; 
Sanchis et al., 2019), Chine (Wu et al., 2010), and New Zealand 
(Mukuddem-Petersen, Stonehouse Oosthuizen, Jerling, Hanekom, & 
White, 2007). The follow-up period ranged from 4 weeks to 2 years. 
Daily recommended amount of walnut intake varied between 6 and 
108 g. All trials were done on both gender except for two studies, one 
including only men (Din et al., 2011) and the other women (Fatahi 
et al., 2019). The sample of the trials ranged from 21 to 636 subjects. 
Participants were patients with metabolic syndrome (n = 3), chronic kid- 
ney disease (CKD) (n = 1), diabetes or at high risk for diabetes (n = 4), 
adults at risk for cardiovascular disease and moderate hypercholesterol- 
emia (n = 4), and healthy subjects (n = 6). Characteristics of included 
studies are summarized in Table 1. Methodological quality and risk of 
bias are displayed in Table S1, with most publications having adequate 
quality for key domains. Taken together, six studies have fair quality, 
three have poor quality, and eight have good quality. 
 
 
3.3 | Meta-analysis results 
 
3.3.1 | Effect of walnut intake on SBP 
 
Eighteen studies, including a total of 1,799 participants (walnut 
group = 917 and control = 882), reported SBP as an outcome. Overall 
results from the random-effects model indicated that walnut intake 
did not result significant change in SBP (WMD: 0.078 mmHg, 95% CI: 
−0.691, 0.848, p = .842), with significant heterogeneity being present 
among the studies (I2 = 85.1%, p = .000) (Figure 2). In subgroup analy- 
sis, we found that healthy status significantly contributed to the het- 
erogeneity score. Moreover, the effect of walnut intake on SBP was 
significant in subjects with metabolic syndrome (WMD: −1.06 mmHg; 
95% CI: −1.41, −0.72, p < .001; I2 = 72%) and in healthy population 
(WMD: −1.29 mmHg; 95%  CI:  −1.42, −1.16, p < .001;  I2 =  63%), 
while it was not significant in patients with type 2 diabetes (WMD: 
0.05 mmHg; 95% CI: −1.03, 1.13, p = .927; I2 = 92%) and 
 
















Sanchis et al. (2019) Spain Patients with chronic kidney Both 324/312 30 days 30 g/day 
  disease     
Al Abdrabalnabi et al. (2020) USA Healthy elderly Both 13/13 2 years 30–65 g/day 
Fatahi et al. (2019) Iran Overweight and obese women Women 33/33 12 weeks 6 g/day 
Hwang et al. (2019) Republic of Subjects with metabolic Both 43/41 16 weeks 45 g/day 
 Korea syndrome     
Tindall et al. (2019) USA Adults at risk for cardiovascular Both 36/36 6 weeks 57–99 g/d 
  disease     
Ndanuko et al. (2018) Australia Overweight/obese adults Both 82/62 3 months 30 g/day 
Rock et al. (2017) USA Nondiabetic overweight and Both 47/50 6 months 28-42 g/day 
  obese men and women    (1–1.5 oz/day) 
Nezhad et al. (2016) Iran Patients with diabetes mellitus Both 45/45 3 months 15 g/day 
type 2 
Njike et al. (2015) USA Adults at risk for diabetes Both 26/23 6 months 56 g or 2 oz/day 
Njike et al. (2015) USA Adults at risk for diabetes Both 26/23 6 months 56 g or 2 oz/day 
Katz et al. (2012) USA Overweight adults with visceral Both 22/18 8 weeks 56 g/day 
  obesity     
Din et al. (2011) UK Healthy males Men 30/30 4 weeks 15 g/day 
Wu et al. (2010) Chinese Adult with metabolic syndrome Both 94/95 12 weeks 30 g/day 
Ma et al. (2010) USA Type 2 diabetes Both 10/11 8 weeks 56 g/day 
Spaccarotella et al. (2008) USA Men at risk for prostate cancer Men 21/21 8 weeks 75 g/day 
Olmedilla-Alonso et al. (2008) Spain Subjects at high cardiovascular Both 25/25 5 weeks 60 g/week 
  risk    walnut paste 
Mukuddem-Petersen New Subjects with metabolic Both 21/22 8 weeks 63 to 108 g/day 
et al. (2007) Zealand syndrome     
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FIG U R E 2 Forest plot of randomized controlled trials that investigated the effects of walnut intake on systolic blood pressure (SBP) [Colour 
figure can be viewed at wileyonlinelibrary.com] 
 
 
cardiovascular disease (WMD:  0.16 mmHg;  95%  CI:  −0.27,  0.60, 
p = .464; I2 = 34%). There was a greater significant reduction in SBP 
for studies with walnut intake >40 g/day (WMD: −1.29 mmHg, 95% 
CI: −1.49, −1.16, p < .001; I2 = 43%) when compared to ≤40 g/day 
(WMD: −0.53 mmHg, 95% CI: −0.80, −0.27, p < .001; I2 = 90%). 
Moreover, the length of intervention ≥8 weeks was linked to a signifi- 
cant reduction in  SBP (WMD: −1.18 mmHg, 95% CI: −1.30, −1.06,   
p < .001; I2 = 82%) (Table S2). 
 
 
3.3.2 | Effect of walnut intake on DBP 
 
Similar to SBP, 18 studies including a total of 1,799 participants (wal- 
nut group = 917 or control = 882) reported DBP as an outcome. Com- 
bined results from the random-effects model indicated that DBP did 
not change significantly following walnut intake (WMD: 0.08 mmHg, 
95% CI: −0.25, 0.42, p = .631), with low heterogeneity being present 
among the studies (I2 = 35.0%, p = .072) (Figure 3). In subgroup analy- 
sis, we found that healthy status, walnut daily dose and treatment 
duration significantly contributed to the heterogeneity score. More- 
over, the effect of walnut intake on DBP was significant in subjects 
with metabolic  syndrome (WMD: 0.22 mmHg; 95% CI: 0.02, 0.42,  
p = .029; I2 = 36.4%)  and  with  cardiovascular  disease  (WMD:  
0.33 mmHg; 95% CI: 0.02, 0.65, p = .033; I2 = 0.0%), whereas it was 
not significant in patients with type 2 diabetes ((WMD: 0.36 mmHg; 
95% CI: 1.06, 1.79, p = .619; I2 = 79%) and healthy subjects (WMD: 
−0.12 mmHg; 95% CI: −0.51, 0.27, p  = .537; I2  = 0.0%). In addition, 
there was a significantly more decrease in DBP for studies with wal- 
nut intake ≤40 g/day (WMD: −0.19 mmHg, 95% CI: −0.348, −0.034, 
p = .017; I2 = 55%) when compared to >40 g/day (WMD: 0.32 mmHg, 
95% CI: −0.54, 1.19, p = .467; I2 = 13.9%). The length of intervention 
≥8 weeks significantly resulted in increased DBP (WMD: 0.22 mmHg, 
95% CI: 0.06, 0.38, p = .005; I2 = 10%) (Table S2). 
 
 
3.3.3 | Nonlinear dose–response between dose 
and duration of walnut consumption and BP 
 
Following dose–response evaluation, walnut intake significantly chan- 
ged SBP (p = .015) and DBP (p = .026) through a nonlinear fashion at 
walnut dose up to 40 g/day. Based on treatment duration, DBP     
(p = .029) significantly reduced as well (Figure 4). 
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FIG U R E 3 Forest plot of randomized controlled trials that investigated the effects of walnut intake on diastolic blood pressure (DBP) [Colour 
figure can be viewed at wileyonlinelibrary.com] 
 
 
3.3.4 | Sensitivity analysis 
 
To discover the impact of each single study on the combined effect 
size, we removed each trial from the analysis, step-by-step. We 
observed no significant effect of any individual study on the combined 
effect sizes for SBP and DBP (Figure S1). 
 
 
3.3.5 | Publication bias 
 
Evaluation of publication bias by visual inspection of funnel plot not 
detected publication bias in the meta-analysis for walnut consumption 
on SBP and DBP values (Figure 5). 
 
 
4 | DISCUSSION 
 
Viewed collectively, this meta-analysis did not support walnut con- 
sumption, per se, as a BP-lowering strategy. This finding is in line with 
results of a previous meta-analysis published by Guasch-Ferre et al., 
who through 26 trials also demonstrated that walnut-rich diet did not 
lead to significant reduction in both SBP and DBP (Guasch-Ferre, Li, 
Hu, Salas-Salvado, & Tobias, 2018). Our meta-analysis provides a 
most updated result, since we included five studies after the year that 
the Guasch-Ferre et al' work was published. 
Regarding the dosage, we included studies with walnut intake 
within a range between 6 and 108 g/day for 4 weeks to 2 years. In 
subgroup analyses, walnut ingestion ≤40 g was statistically correlated 
to reduction in SBP (WMD: −0.53 mmHg, 95% CI: −0.79, −0.26) and 
DBP (WMD: −0.191 mmHg, 95% CI: −0.384, −0.034), and >40 g was 
statistically  correlated only  to  SBP  (WMD: −1.292 mmHg,  95% CI: 
−1.420, −1.164). Concerning the treatment duration, <8 weeks was 
statistically correlated to increased SBP (WMD: 1.251 mmHg, 95% CI: 
0.252, 2.249) while it did not change for DBP (WMD: −0.416 mmHg, 
95%   CI:   −1.139,   −0.307).   Differently,   SBP   decreased  (WMD: 
−1.180 mmHg, 95% CI: −1.296, −1.064) while DBP increased (WMD: 
0.224 mmHg, 95% CI: 0.066, 0.382) for ≥8 weeks. In other words, 
both decrease and increase in BP were detected depending on the 
variable, with paradoxical findings being noted in an attempt to search 
an ideal cutoff point for daily dose and length of intervention. Alto- 
gether, these changes are linked to statistical implication, but when 
translating into clinical practice the data are modest. For instance, we 
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FIG U R E 4 Nonlinear dose-responses between walnut consumption and blood pressure (BP) measurements. The 95% confidence interval 
(CI) is depicted in the shaded regions [Colour figure can be viewed at wileyonlinelibrary.com] 
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FIG U R E 5 Funnel plot of the weighted mean difference (WMD) versus the s.e. of the WMD [Colour figure can be viewed at 
wileyonlinelibrary.com] 
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cannot to draw recommendation based on these sub-analyses 
because the majority of statistical changes were related to <1 mmHg 
of both SBP and DBP, so that a positive or negative alteration of 
approximately 1 mmHg of BP is a very small clinical difference, espe- 
cially taking into account the BP categories: <120/80 mmHg, 120–
129/<80 mmHg, 130–139/80–89 mmHg, >140/80 mmHg, for normal, 
elevated, stage 1 and stage 2,  respectively;  SBP  over 180 mmHg 
and/or DBP over 120 mmHg are classified as hyperten- sive crisis 
(JACC, 2017). Given that patients with elevated or at stages 1 or 2 of 
BP categories would be more likely to obtain benefits from 
nutraceutical strategies, an alteration of 1 mmHg indeed is minimal. 
Such a variation may occur due to error during the measurement, as 
the accuracy is determined by the experience and adequate training 
of the health professional responsible for data collection, as well as by 
the monitor, whether it is a manual or digital meter. Moreover, follow- 
up in nutritional interventions commonly did not employ blinding, 
once foodstuffs differ from pills. It is therefore important to mention 
that the lack of blinding is a confounding factor that has not been con- 
trolled, which may positively affect the measurement of BP by an indi- 
vidual believe that dietary intervention will improve this parameter or 
adversely affect BP simply due to the popular white coat syndrome 
(Pioli, Ritter, de Faria, & Modolo, 2018). 
Not only were the sub-analyses for walnut dosage puzzling, but 
also for healthy status, which involved patients with car- 
diometabolic dysregulations and healthy subjects. Correspondingly, 
decreased   SBP    was    correlated   with   being   healthy   (WMD: 
−1.290 mmHg, 95% CI: −1.418, −1.161) and having metabolic syn- 
drome  (WMD:  −1.062 mmHg,  95%  CI:  −1.407,  −0.718).  Another 
paradoxical result was the correlation of increased DBP with 
patients with metabolic syndrome (WMD: 0.225 mmHg, 95% CI: 
0.023, 0.427) and cardiovascular disease (WMD: 0.339 mmHg, 95% 
CI: 0.027, 0.651). There is no physiological explication for these 
findings, as an additional dietary-lowering effect is usually more jus- 
tified in patients with cardiometabolic dysregulation. Despite these 
inconsistences, in a well-designed trial involving 30–60 g/day of 
walnuts,  elderly  subjects  with  baseline  24-hr  ambulatory  SBP 
>125 mmHg have a significant decrease of 8.5 mmHg under a 2-
year follow-up (Domènech et al., 2019). In general, DBP did not 
change but, most importantly, patients who received walnut needed 
less antihypertensive medication than controls. Such a SBP decrease 
of 8.5 mmHg is better than any result obtained by this meta-analysis. 
Thus, perhaps walnut intake can be an adjuvant dietary tool in the 
control of hypertension but, ideally, further long-term investigations 
are imperative, particularly encompassing patients with hypertension 
and using 24-hr ambulatory BP monitoring, since it is the gold stan- 
dard for diagnosing this disease (Kinsara, 2017). 
Recently, we published another meta-analysis (Fang et al., 2020) 
by which we did not find positive effect of incorporating walnut into 
diets to improve anthropometric characteristics used in weight loss 
monitoring (body weight, body mass index, waist circumference, and 
fat mass). Thus, coupled with the present finding, this suggests 
another neutral effect of the walnuts instead of improving clinical pro- 
posals. In addition to the lowering-BP effect, some studies also show 
that nuts intake may be an approach to enhancing weight loss     
(de Souza, Gomes, de Castro, & Mota, 2018; Rock et al., 2017), which 
may ensue in decreased BP as well. At least pertaining to walnuts, our 
recent meta-analyses did not corroborate shifts in BP and anthropo- 
metric characteristics when viewed as a whole. 
Although we have already discussed the divergence between 
statistical and biological data, it is crucial to explain the traditional 
recommendation for the management of hypertension, as available 
on guidelines. Upon dietary habits, it should be considered: (a) a 
healthy eating plain based on vegetables, low-fat dairy products, 
whole-grain foods, and plant proteins; (b) reducing sodium intake to 
2 g/day (5 g of salt); (c)  increasing  dietary  potassium  intake 
(e.g., avocado, banana, cocoa powder, and potato); (d) limiting alco- 
hol ingestion to <2 drinks per day, whose consumption does not 
exceed 14 standard drinks per week for men and 9 for women 
(Nerenberg et al., 2018). Avoiding excessive intake of carbohydrates, 
particularly sugar, is another nutritional concern in the treatment of 
hypertension, as the insulin resistance affects blood vessels due to 
the activation of the cardiovascular tissue renin–angiotensin– 
aldosterone system (Manrique, Lastra, & Sowers, 2014). Hence, lim- 
iting hyper-palatable foods is important, such as traditional food 
items of cafeteria diets. 
Among other nonpharmacological strategies, that is, health 
behavior management, are: (a) physical exercise: 30–60 min of 
moderate-intensity dynamic exercise, 4–7 days/week beyond the rou- 
tine activities; (b) body weight loss itself; (c) stress management, such 
as an individualized cognitive-behavioral intervention (Nerenberg 
et al., 2018). Regarding pharmacological treatment, as a general rule, 
the therapy can be based on an individualized strategy, including 
either monotherapy or combination of: thiazide/thiazide-like diuretic, 
β-blocker, angiotensin-converting enzyme inhibitors, and long-acting 
calcium channel blocker (Nerenberg et al., 2018; Whelton, Carey, & 
Aronow, 2018; Whelton, et al., 2018. After these recognizable points, 
walnuts can be regarded only as an adjuvant foodstuff that putatively 
may exert some cardiometabolic improvements but without necessar- 
ily decreasing BP. Apart from walnuts, other nuts should be consid- 
ered to allow long-term adherence in clinical practice. 
The exact mechanism by which walnut ingestion may improve 
BP remains uncertain. Walnuts have relatively high levels of arginine 
compared to other amino acids (Mapelli, Brambilla, & Bertani, 2001), 
which is the precursor amino acid of endogenous vasodilator nitric 
oxide (NO) (Ros et al., 2004). NO is a potent vasodilator that acts via 
the second intracellular cyclic guanosine-50-monophosphate (Bode- 
Boger et al., 1996), so that impaired NO bioactivity is implicated in 
arterial stiffness (Hermann, 2007). Moreover, diminished arginine 
bioavailability and its increased catabolism are associated with 
increased   cardiovascular   risk   (Tang,   Wang,   Cho,   Brennan,   & 
Hazen, 2009). Against all putative effects, 100 g of walnuts contain 
approximately 1.5 g of l-arginine, while the body of evidence favor- 
ing the oral arginine supplementation in decreasing BP ranges from 
4 to 24 g/day (Dong et al., 2011). Therefore, the arginine amount in 




Bearing in mind a nutritional explanation for oleaginous fruits, 
walnut is highlighted due to its greater amount of total phenols and 
antioxidant  potential  (approximately  2,500 mg  total   phenol 
and approximately 120 μmol trolex eq/g antioxidant capacity in 100 g 
of fresh walnut weight) (Abe, Lajolo, & Genovese, 2010), which are 
factors that can modulate endothelial cells and hence being conceiv- 
able to improve BP. In addition, walnuts are a source of magnesium, 
potassium and zinc (USDA, 2020), which are well-known minerals 
with lowering-BP effects, as showed by meta-analyses (Kass, 
Weekes, & Carpenter,  2012;  Mousavi  et  al.,  2020;  Poorolajal  
et al., 2017). However, the content of zinc and magnesium in walnuts, 
as well as in any oleaginous fruits, cannot be compared to the effec- 
tive dosage of these minerals for decreasing BP. For example, 100 g 
of walnuts contain 158 mg of magnesium, 441 mg of potassium, 3 mg 
of zinc (USDA, 2020), which are doses that just complement the daily 
requirement of these minerals, while the benefits are mainly caused 
by pharmacological doses. Along these lines, the magnitude of these 
minerals in improving BP is slight when compared their ingestion 
across walnuts to elemental doses used in supplementation. Yet, in a 
common walnut serving (approximately 30 g), the amount of magne- 
sium, potassium and zinc drops to 47, 132, and 1 mg, respectively. 
Whereas the principle of nutrition, that is, the long-term adherence 
together moderate consumption of any food item or nutrient, it is 
unfeasible to intake a large amount of walnuts or any oleaginous fruits 
to obtain great doses of minerals. Most importantly, n-3 PUFA intake 
or its supplementation is a well-studied approach for patients with 
hypertension (Miller, Van Elswyk, & Alexander, 2014), and walnuts are 
a vegetable source of n-3 PUFA. Walnuts contain approximately 9 g 
of ALA per 100 g, which nutritionally is conceivable to exert physio- 
logical and clinical benefits. Accordingly, a Cochrane's meta-analysis 
(Abdelhamid et al., 2018) of RCTs demonstrated that fish oil supple- 
mentation did not lead improvements in primary endpoints (all-cause 
deaths and cardiovascular events), while sub-analyses for ALA demon- 
strated some favorable effects in this setting. 
It is crucial to highlight that heterogeneity was detected in many 
sub-analyses. This is a limitation of our study, since heterogeneity 
reflects a diversity of the studied population whereby influencing our 
results. On the other hand, we carried out sub-analyses on healthy 
status and dose–response, and heterogeneity is common among 
meta-analyses, as the creation of different study designs to answer 
new questions is a scientific basis. Another limitation is the follow-up 
period, which ranged from 4 weeks to 2 years and, therefore, long- 
term effects (i.e., years) of walnut consumption on BP cannot be esti- 
mated. Only two included studies were carried out on a ≥1 year 
follow-up (Al Abdrabalnabi et al., 2020; Sanchis et al., 2019). 
As a strong point, this is an updated meta-analysis by which we 
demonstrate and discuss the mismatch between statistical and biolog- 
ical meaningful, not translating sub-analyses into conclusion to avoid 
unwarranted applicability in clinical practice. The overall result gener- 
ated herein is the main finding, that is, neutral or a lack of effects. This 
is the best and the effortless way to deciphering the message of the 
present meta-analysis, which also adds importance to the literature, 
once negative results (i.e., circumstances where the treatment being 
tested had no effect) are just as essential as positive results. Ulti- 
mately, to the best of our knowledge, this is the first meta-analysis of 
RCTs that examined the dose–response of walnut intake on BP, pro- 
viding more nuanced guidance for future investigations. 
 
 
5 | CONCLUSION 
 
This meta-analysis does not support walnut consumption as a BP- 
lowering strategy. Walnuts can be regarded only as a complementary 
foodstuff in a healthy eating plan, but without necessarily lowering 
BP. At best, walnuts are a source of zinc, magnesium, potassium, fiber, 
antioxidants, and ALA, and are endorsed to be a potential functional 
food item to improve lipid indices. Among clinical practice, long-term 
adherence should be considered and, thus, it is conceivable that peo- 
ple use other nuts to obtain more variability. 
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